Fibrates for secondary prevention of cardiovascular disease and stroke (Q24186376)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

meta-analysis

0 references

title

Fibrates for secondary prevention of cardiovascular disease and stroke (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

main subject

cardiovascular disease

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Bian Liu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Wendan Tao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Zilong Hao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Ming Liu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

25 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

CD009580

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

Effects of combination lipid therapy in type 2 diabetes mellitus

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Expert commentary: the safety of fibrates in lipid-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Atherosclerosis in 2010: new therapeutic insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Fibrates for primary prevention of cardiovascular disease events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Efficacy of Gemfibrozil in Dyslipidaemic Subjects with Suspected Heart Disease. An Ancillary Study in the Helsinki Heart Study Frame Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009580.PUB2

Clofibrate and niacin in coronary heart disease

21 January 2018

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421

1 reference

12 December 2020

A One Year Double Blind Study Of The Effect Of Halofenate And Clofibrate In Patients With Hyperlipoproteinemia

1 reference

12 December 2020

Lipids and risk of coronary heart disease. The Framingham Study

1 reference

12 December 2020

Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial

1 reference

12 December 2020

The use of fibric Acid derivatives in cardiovascular prevention

1 reference

12 December 2020

Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance

1 reference

12 December 2020

Clofibrate for the treatment of occlusive cerebrovascular disease

1 reference

12 December 2020

Controlled trial of clofibrate in cerebral vascular disease

1 reference

12 December 2020

Ischemic heart disease: a secondary prevention trial using clofibrate (Atromid-S).

1 reference

12 December 2020

The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section

1 reference

12 December 2020

Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region

1 reference

12 December 2020

Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians

1 reference

12 December 2020

Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia

1 reference

12 December 2020

Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment

1 reference

12 December 2020

Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

1 reference

12 December 2020

Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

1 reference

12 December 2020

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

12 December 2020

Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study

1 reference

12 December 2020

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

1 reference

12 December 2020

10.1002/14651858.CD009580.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497361%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference